A Phase I/II Study of the Oral MDM2 Inhibitor DS-3032b in Combination With Low Dose Cytarabine (LDAC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase of Trial: Phase I/II
Latest Information Update: 19 Jul 2019
Price : $35 *
At a glance
- Drugs Cytarabine (Primary) ; Milademetan (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 11 Jul 2019 Planned number of patients changed from 52 to 32.
- 11 Jul 2019 Planned End Date changed from 1 May 2020 to 1 May 2021.
- 17 Dec 2018 Status changed from not yet recruiting to recruiting.